KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:待检查 入排置信度 0.98

Multimodal prognostic modeling of individual cognitive trajectories to enhance trial efficiency in preclinical Alzheimer's disease.

Viswanath Devanarayan, Michael C Donohue, Reisa A Sperling, Keith A Johnson, Yuanqing Ye, Arnaud Charil, Thomas Doherty, Lu Tian, Rema Raman, Paul S Aisen, Lynn D Kramer, Michael C Irizarry, Shobha Dhadda

Alzheimers Dement 21(9) e70702

PMID40990131
PMCIDPMC12457986
DOI10.1002/alz.70702
发表日期2025-09-24
入排依据:未发现恶性肿瘤人群证据。
入排复审未纳入:未发现恶性肿瘤人群证据。
摘要

摘要

INTRODUCTION: Cognitive decline in asymptomatic preclinical Alzheimer's disease (AD) is slow and variable, limiting detection of treatment effects. This study developed models to forecast trajectories and improve trial efficiency. METHODS: Models were trained on longitudinal Preclinical Alzheimer's Cognitive Composite (PACC) data up to 240 weeks from the Phase III A4 study of solanezumab. Baseline inputs included demographics, apolipoprotein E (APOE) ε4, clinical scores, amyloid positron emission tomography (PET), plasma pTau217, magnetic resonance imaging (MRI), and tau PET (sub-study). Stochastic gradient boosting was used, with evaluation via cross-validation and trial simulations. RESULTS: The best model without tau PET used pTau217, clinical, and MRI data (R2 = 0.32; area under the receiver operating characteristic curve (AUROC) for classifying a 0.5-point PACC decline = 78.6%). Replacing MRI with tau PET improved performance (R2 = 0.42; AUROC = 83.1%). Predicted trajectories as a prognostic covariate reduced sample sizes by 35% and increased power from 80% to 94.7%. DISCUSSION: Prognostic models can predict decline in preclinical AD and improve trial efficiency. GOV IDENTIFIERS: NCT02008357 (Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4)) HIGHLIGHTS: Models forecast 4.5-year cognitive decline in amyloid-positive preclinical Alzheimer's disease (AD). Plasma pTau217 and tau positron emission tomography (PET) standardized uptake value ratios (SUVRs) in early-accumulating regions are key predictors. Tau PET improves prediction beyond plasma, magnetic resonance imaging (MRI), and clinical measures. Forecasted decline as a prognostic covariate improves power and cuts sample size in trial simulations. Alternative models underperform yet retain practical utility when tau PET or pTau217 is unavailable.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。